ReviewFrontiers in cell and developmental biology2020
Enhancement of the Therapeutic Capacity of Mesenchymal Stem Cells by Genetic Modification: A Systematic Review.
Review in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Recombinant human adenovirus p53 combined with transcatheter arterial chemoembolization for liver cancer: A meta-analysis.PloS one · 2023Pooled it
- Decoding, Mapping, and Designing: A New Paradigm for Harnessing Umbilical Cord Mesenchymal Stem Cell Heterogeneity in Obstetric Precision Therapy.Stem cell reviews and reports · 2026Review
- Smart integrated biomaterial systems for precision and optimized delivery of MSCs and their exosomes: Transforming wound healing and organ regeneration.Regenerative therapy · 2026Review
- Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.Frontiers in molecular neuroscience · 2026Review
- Genetic Engineering of Umbilical Cord-Derived Mesenchymal Stem Cells to Enhance BMP-2 Secretion via Signal Peptide Optimization.Biomedicines · 2025Article
- Innovative strategies to enhance MSCs efficacy in acute kidney injury (Review).International journal of molecular medicine · 2025Review
- MSCs engineered with secreted Klotho alleviate blood-brain barrier disruption and reduce neuroinflammation more effectively than MSCs in experimental autoimmune encephalomyelitis.Stem cell research & therapy · 2025Article
- Novel PEI-aldehyde conjugates for gene delivery: Promoting chondrogenic differentiation in human mesenchymal stem cells.Molecular therapy. Nucleic acids · 2025Article
- Dual facets of MSC-derived small EVs: regulatory insights into antitumor mechanisms in pancreatic ductal adenocarcinoma.Medical oncology (Northwood, London, England) · 2025Article
- Antitumor Efficacy of Interleukin 12-Transfected Mesenchymal Stem Cells in B16-F10 Mouse Melanoma Tumor Model.Pharmaceutics · 2025Article
- Synergistic Antioxidant Effects of Molecular Hydrogen and Cold Atmospheric Plasma in Enhancing Mesenchymal Stem Cell Therapy.Antioxidants (Basel, Switzerland) · 2024Review
- Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis.Bioengineering (Basel, Switzerland) · 2024Review
- Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment.Advanced pharmaceutical bulletin · 2024Review
- Article
- Chemical Coaxing of Mesenchymal Stromal Cells by Drug Repositioning for Nestin Induction.International journal of molecular sciences · 2024Article
- Manufacturing mesenchymal stromal cells in a microcarrier-microbioreactor platform can enhance cell yield and quality attributes: case study for acute respiratory distress syndrome.Journal of translational medicine · 2024Article
- Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.International journal of molecular sciences · 2024Review
- Current Strategies and Therapeutic Applications of Mesenchymal Stem Cell-Based Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Emerging technology has a brilliant future: the CRISPR-Cas system for senescence, inflammation, and cartilage repair in osteoarthritis.Cellular & molecular biology letters · 2024Review
- Revolutionizing bone defect healing: the power of mesenchymal stem cells as seeds.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundThe therapeutic capacity of mesenchymal stem cells (also known as mesenchymal stromal cells/MSCs) depends on their ability to respond to the need of the damaged tissue by secreting beneficial paracrine factors. MSCs can be genetically engineered to express certain beneficial factors. The aim of this systematic review is to compile and analyze published scientific literatures that report the use of engineered MSCs for the treatment of various diseases/conditions, to discuss the mechanisms of action, and to assess the efficacy of engineered MSC treatment.
methodsWe retrieved all published studies in PubMed/MEDLINE and Cochrane Library on July 27, 2019, without time restriction using the following keywords: "engineered MSC" and "therapy" or "manipulated MSC" and "therapy." In addition, relevant articles that were found during full text search were added. We identified 85 articles that were reviewed in this paper.
resultsOf the 85 articles reviewed, 51 studies reported the use of engineered MSCs to treat tumor/cancer/malignancy/metastasis, whereas the other 34 studies tested engineered MSCs in treating non-tumor conditions. Most of the studies reported the use of MSCs in animal models, with only one study reporting a trial in human subjects. Thirty nine studies showed that the expression of beneficial paracrine factors would significantly enhance the therapeutic effects of the MSCs, whereas thirty three studies showed moderate effects, and one study in humans reported no effect. The mechanisms of action for MSC-based cancer treatment include the expression of "suicide genes," induction of tumor cell apoptosis, and delivery of cytokines to induce an immune response against cancer cells. In the context of the treatment of non-cancerous diseases, the mechanism described in the reviewed papers included the expression of angiogenic, osteogenic, and growth factors.
conclusionThe therapeutic capacity of MSCs can be enhanced by inducing the expression of certain paracrine factors by genetic modification. Genetically engineered MSCs have been used successfully in various animal models of diseases. However, the results should be interpreted cautiously because animal models might not perfectly represent real human diseases. Therefore, further studies are needed to explore the translational potential of genetically engineered MSCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.